Physician profile
Bakulkumar M Patel
NPI 1093727869
$5,901.61
in general payments reported to CMS, 2019-2025
56 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $639 · 2021: $753 · 2022: $1,232 · 2023: $921 · 2024: $677 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.34 | 2021-2025 | |
| Eisai INC. | $546.28 | 2019-2020 | |
| Amgen INC. | $536.53 | 2019-2025 | Repatha, Prolia, Evenity |
| Novo Nordisk INC | $284.76 | 2021-2025 | Ozempic |
| Lilly USA, LLC | $224.27 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sk Life Science, INC. | $208.17 | 2020-2023 | |
| Eli Lilly and Company | $175.00 | 2021 | |
| Allergan, INC. | $170.56 | 2020 | |
| Ucb, INC. | $170.13 | 2021-2025 | Nayzilam, Rystiggo |
| Dexcom, INC. | $162.03 | 2023-2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $156.35 | 2019-2025 | Injectafer |
| Vertiflex, INC. | $152.20 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $143.79 | 2023-2024 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $142.84 | 2024-2025 | Eohilia |
| Argenx US, INC. | $140.72 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bakulkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.